Harmony Biosciences
HRMY
234 hedge funds and large institutions have $2.01B invested in Harmony Biosciences in 2024 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 72 increasing their positions, 87 reducing their positions, and 22 closing their positions.
119% more call options, than puts
Call options by funds: $4.39M | Put options by funds: $2M
73% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 22
33% more capital invested
Capital invested by funds: $1.51B → $2.01B (+$493M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
7% more funds holding
Funds holding: 219 → 234 (+15)
0.06% less ownership
Funds ownership: 88.33% → 88.26% (-0.06%)
17% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 87
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIM
Cambria Investment Management
Manhattan Beach,
California
|
+$11.6M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$11.2M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$9.68M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.78M |
| 5 |
LSV Asset Management
Chicago,
Illinois
|
+$6.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$20.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$18.6M |
| 3 |
VP
venBio Partners
San Francisco,
California
|
-$14.8M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$8.92M |
| 5 |
Millennium Management
New York
|
-$8.31M |
HRMY Hedge Fund Activity: Q3 2024 in Review
234 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q3 2024, worth a combined $2.01B — up 33% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new HRMY positions and 22 closed out — a net gain of 16 holders — while 72 added to existing stakes and 87 trimmed.
The largest buyer was Cambria Investment Management, opening a new position worth an estimated $11.6M. The largest seller was Pacer Advisors, cutting an estimated $20.4M.
- 234 institutional investors held Harmony Biosciences (HRMY) as of Q3 2024, up from 219 in Q2 2024.
- Funds reported $2.01B of Harmony Biosciences stock for Q3 2024, up 33% quarter-over-quarter.
- 38 funds opened new Harmony Biosciences positions in Q3 2024 and 22 closed out, a net change of +16 holders.
- The largest Harmony Biosciences buyer in Q3 2024 was Cambria Investment Management, an estimated $11.6M added.
- The largest Harmony Biosciences seller in Q3 2024 was Pacer Advisors, an estimated $20.4M sold.
Based on aggregated 13F filings for Q3 2024.